Project: Development of a first-in-class peptide therapy for treatment of diabetes
| Acronym | DIA-PEP (Reference Number: 113230) |
| Duration | 01/12/2019 - 03/12/2022 |
| Project Topic | The DIA-PEP consortium will develop FOL-014, a first-in-class peptide drug for treatment of type 2 diabetes (T2D). FOL-014 uniquely targets a novel molecular pathway to induce insulin-secretion, while protecting/preserving pancreatic ß-cells and preventing atherosclerotic plaque instability. During this project, we will perform the necessary preclinical development to deliver a new candidate drug to treat T2D, allowing for subsequent GMP production, safety studies and clinical validation |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Follicum AB | Partner | Sweden |
| 2 | Lund University | Partner | Sweden |
| 3 | Bioassay Labor für biologische Analytik GmbH | Partner | Germany |
| 4 | Deutsche Diabetes-Forschungsgesellschaft | Partner | Germany |